EU/3/16/1759 - orphan designation for treatment of Duchenne muscular dystrophy

Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter

Overview

On 14 October 2016, orphan designation (EU/3/16/1759) was granted by the European Commission to Pharma Gateway AB, Sweden, for recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter (also known as SGT-001) for the treatment of Duchenne muscular dystrophy.

What is Duchenne muscular dystrophy?

Duchenne muscular dystrophy (DMD) is a genetic disease that gradually causes weakness and atrophy (wasting) of muscles. It mainly affects boys, and usually starts before the age of six years. The muscle weakness usually starts in the hips and legs, before affecting the arms, chest and the heart. Patients with DMD lack normal dystrophin, a protein found in muscles. Because this protein helps to protect muscles from injury as muscles contract and relax, in patients with DMD the muscles become weaker and eventually stop working.

DMD causes long-term disability and is life threatening because of its effects on the heart and the respiratory muscles (muscles that are used to breathe). The disease usually leads to death in early adulthood.

What is the estimated number of patients affected by the condition?

At the time of designation, DMD affected less than 0.5 in 10,000 people in the European Union (EU). This was equivalent to fewer than 26,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 513,700,000 (Eurostat 2016).

What treatments are available?

At the time of designation, the medicine Translarna (ataluren) was authorised in the EU for the treatment of a small group of patients with DMD due to a particular type of mutation, called a nonsense mutation, in the dystrophin gene. Patients also received supportive treatment such as physiotherapy.

The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with DMD because data in experimental models show that it can potentially be used in a wider group of patients than the currently authorised treatment. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

The medicine consists of a virus that contains a copy of the microdystrophin gene. This gene produces 'microdystrophin', a protein that works like dystrophin but is smaller. When given by injection to the patient, it is expected that the virus will carry the gene into the muscle cells, enabling them to produce the microdystrophin protein. This is then expected to reduce muscle wasting, slowing down progression of the condition.

The virus used in this medicine (adeno-associated virus) does not cause disease in humans.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with DMD had been started.

At the time of submission, the medicine was not authorised anywhere in the EU for DMD. Orphan designation of the medicine has been granted in United States. for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 8 September 2016 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/16/1759: Public summary of positive opinion for orphan designation of recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter for the treatmen...

AdoptedReference Number: EMA/614751/2016

Key facts

• Active substance:
  Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter
• Intended use:
  Treatment of Duchenne muscular dystrophy
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/16/1759
• Date of designation:
  14/10/2016
• Sponsor:

  Voisin Consulting Life Sciences;